However, many preclinical and clinical studies have identified abnormal HER2 protein expression, gene amplification, and mutations in various malignancies of epithelial origin, especially cancers of the breast, stomach, ovary, and bladder [16,17,18]. This evidence concerns the gene ERBB2 and cancer.